Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
168
resultados
Última actualización
15/09/2026 [09:42:00]
Resumen de: WO2026185106A1
The present invention relates to the use of a pharmaceutical combination comprising molecules that rebilance the pathway of the epigenetic modulators LiN28, EZH2 and Let-7 and increases the expression of GFAP protein in particular in the treatment of all the diseases of the central nervous system (CNS) wherein LiN28, EZH2 and Let-7 dysregulation influence the expression of GFAP gene, selected from Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Schizophrenia, Bipolar Disorder, Fetal alcohol spectrum disorder and Autism. The invention further relates to the use of a pharmaceutical composition comprising said combination and at least one pharmaceutical acceptable excipient in the treatment and/or prevention of neurodegenerative diseases and neurodevelopment diseases.
Resumen de: US20260263349A1
A delayed timed release pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a tablet core. The tablet core comprises a drug-containing layer and a boosting layer stacked on the drug-containing layer. The drug-containing layer comprises a drug active ingredient. The drug active ingredient is levodopa or a derivative thereof, or a mixture of levodopa or a derivative thereof and a DOPA decarboxylase inhibitor, and accounts for 5-72.5 wt % of the content of the drug-containing layer. The pharmaceutical composition is a capsule-shaped tablet, can realize the effects of 1-3 h delayed release of the drug active ingredient and reaching a peak concentration at 6-10 h, can be used for reducing morning stiffness in patients with Parkinson's disease, and has good application prospects.
Resumen de: AU2025231257A1
The present invention relates to peptides for treatment of cognitive diseases, in particular Alzeheimer's Disease, mild cognitive impairment due to Alzheimer's disease, and mild dementia due to Alzheimer's disease.
Resumen de: AU2025234423A1
Provided are compositions for delivery of zinc finger fusion proteins that inhibit expression of tau in the nervous system using the blood-brain barrier penetrant AAV capsid proteins comprising SEQ ID. NO: 1235, and methods of using the compositions to treat neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and other tauopathies.
Resumen de: US20260265261A1
Compounds of Formula I:and pharmaceutically acceptable salts thereof are provided for as inhibitors of SGK-1 for example for the treatment of conditions such as Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, stent failure, prostate cancer, epilepsy, colorectal cancer, breast cancer, Parkinson's disease and Lafora disease.
Resumen de: US20260263373A1
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
Resumen de: WO2026184543A1
Provided are a magnetogenetic system based on a clMagR gene and a use thereof in Parkinson's disease. The clMagR gene is injected into neurons by means of an adeno-associated virus (AAV) vector, and on the basis of exogenous iron and magnetic field stimulation technology, a biological function of cells or tissues is regulated. Compared with optogenetics, the system avoids optical fiber implantation and direct light source irradiation required for optogenetics by means of precise control of an external magnetic field, reduces the risk of invasive surgery, and can more widely regulate cell functions in deep neural regions in the body, especially in deep brain regions. Compared with traditional treatment methods, the present invention provides a non-invasive and regulatable gene therapy strategy, providing a new technical paradigm for fields such as stem cell therapy, nerve regeneration, drug delivery, and elucidation of the neural circuit mechanism of diseases.
Resumen de: WO2026185857A1
A method for preventing and/or treating a disease or disorder selected from the group consisting of neurodegenerative disease, hepatic or renal disease, pulmonary disease, cardiovascular disease, cerebrovascular disease, metabolic disease, diabetes mellitus, substance use disorder (SUD), solid tumor, and any combination thereof, by administering a therapeutically effective amount of at least one anti-protozoal compound, e.g., anti-malarial and/or anti-toxoplasma compound, potentially targeting Plasmodium and/or Toxoplasma gondii. The composition may include atovaquone, proguanil, or a combination thereof with possible adjunctive therapies. Further provided are methods and kits for diagnosing Alzheimer's disease or determining an increased risk of developing Alzheimer's disease in a subject.
Resumen de: WO2026185478A1
The present invention relates to compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with Tau protein aggregates, including, but not limited to, Alzheimer's disease (AD). The present invention also relates to, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with Tau protein aggregates.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: WO2026187862A1
Disclosed herein are compounds of the formula: (I), as well as pharmaceutical compositions thereof, wherein the variables are defined herein. In some aspects, the compounds and compositions provided herein may be used to treat neurodegenerative disorders, such as Alzheimer's disease. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof.
Resumen de: WO2026187186A1
The present invention relates to a vanillic acid derivative compound that can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention can be used as a therapeutic agent for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a therapeutic agent composition for Alzheimer's disease and a therapeutic agent composition for neuroinflammation, each comprising the compound.
Resumen de: WO2026188223A1
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions such as Huntington's Disease.
Resumen de: WO2026183787A1
Provided is a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis represented by the following Formula (I). Also provided is a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis.
Resumen de: WO2026188235A1
The present disclosure relates to methods of preventing and/or treating neuroinflammation in a subject in need thereof. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., Amyotrophic lateral sclerosis (ALS)) in vitro. The methods comprise administering one or more Angiotensin II Receptor I Blocker (ARB) to the subject. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., ALS) in vitro.
Resumen de: AU2025232421A1
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.
Resumen de: US20260263525A1
A cell culture protocol for obtaining neural progenitor cells from induced pluripotent stem cells is described. Also described are a pharmaceutical composition and a medicament containing the neural progenitor stem cells for use in the treatment of neuro degenerative disorders such as Parkinson's disease as described.
Resumen de: US20260256865A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, comprising, as an active ingredient, a mulberry fruit extract fermented with lactic acid bacteria. The mulberry fruit extract fermented with lactic acid bacteria improves memory and cognitive function, and thus can exhibit excellent effects on preventing, alleviating or treating Alzheimer's disease.
Resumen de: WO2026179739A1
Disclosed in the present invention are an aminothiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, which belong to the field of medicine. The aminothiazole compound provided in the present invention has a general structural formula represented by formula (I) and comprises a pharmaceutically acceptable salt. The aminothiazole compound of the present invention has histamine H2 receptor agonist activity and excellent blood-brain barrier permeability. Therefore, the aminothiazole compound can be used in the preparation of a medicament for treating schizophrenia, mania, attention deficit hyperactivity disorder, binge eating disorder or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury, and other diseases.
Resumen de: WO2026183114A2
The present disclosure provides, among other things, methods for restoring neuronal function in a subject in need thereof, methods for treating a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury, and methods for improving one or more brain functions in a subject in need thereof. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII).
Resumen de: US20260256860A1
A traditional Chinese medicine composition for treating amyotrophic lateral sclerosis and the use thereof. The composition is prepared by means of combining Ginseng radix et rhizoma and Cistanches herba.
Resumen de: WO2026183116A2
The present disclosure provides, among other things, methods for restoring neuronal cell function in a subject having a brain-related disorder and methods for improving one or more brain functions in a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII). The present disclosure also provides a composition comprising one or more peptide inhibitors of Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII inhibitor peptides).
Resumen de: US20260256960A1
Novel lysosomal acid lipase (LAL) positron emission tomography ligands are provided. Also disclosed herein are methods of assessing the risk of developing Alzheimer's disease (AD) or Alzheimer's Disease Related Dementias (ADRD) and methods of diagnosing AD/ADRD in a subject comprising measuring levels of LAL and optionally LAL accumulation in the subject. Methods of treatment comprising administering LAL are also provided.
Resumen de: US20260256889A1
0000 Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.
Nº publicación: WO2026183555A1 03/09/2026
Solicitante:
WASHINGTON UNIV [US]
WASHINGTON UNIVERSITY
Resumen de: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
BOPI
Sede Electrónica
